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Background. Progressive visual field defects, such as age-related macular degeneration and glaucoma, prevent normal
stimulation of visual cortex. We investigated whether in the case of visual field defects, concentrations of metabolites such as
N-acetylaspartate (NAA), a marker for degenerative processes, are reduced in the occipital brain region. Methodology/
Principal Findings. Participants known with glaucoma, age-related macular degeneration (the two leading causes of visual
impairment in the developed world), and controls were examined by proton MR spectroscopic (
1H-MRS) imaging. Absolute
NAA, Creatine and Choline concentrations were derived from a single-voxel in the occipital region of each brain hemisphere.
No significant differences in metabolites concentrations were found between the three groups. Conclusions/Significance.
We conclude that progressive retinal visual field defects do not affect metabolite concentration in visual brain areas
suggesting that there is no ongoing occipital degeneration. We discuss the possibility that metabolite change is too slow to be
detectable.
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INTRODUCTION
The two leading causes of visual impairment in the developed
world, age-related macular degeneration (AMD) and glaucoma
[1], are affected by progressive retinal visual field defects. Due to
the retinotopic cortical organisation, when these field defects occur
in both eyes and overlap, a corresponding section of visual cortex
no longer receives stimulation. It is known that prolonged absence
of stimulation may result in cortical changes [2,3]. In this paper,
we studied if the concentrations in the occipital brain of the
metabolites N-acetylaspartate (NAA) (a marker of neuronal
integrity), Creatine (Cr) and Choline (Cho) are affected by
progressive visual field defects. Absolute concentrations of these
compounds were measured in the occipital region using single-
voxel proton magnetic resonance spectroscopy (
1H-MRS) in each
hemisphere of AMD and glaucoma patients and a control group.
1H-MRS is a non-invasive technique that allows detection and
quantification of certain biochemical compounds in brain tissue,
such as NAA, Cr, Cho, and lipids [4,5]. NAA is found at relatively
high concentrations in the human central nervous system and is
particularly localized within neurons and related to neuronal
processes [4,6]. A decrease in its concentration is routinely
considered as an indicator of neuronal loss or dysfunction [7,8]
and has been observed in different brain regions in various
neurodegenerative disorders [5,9–13] and neuro-ophthalmology
[14]. Its decrease is mostly observed at the moment when the
disease is in progression. Cr, which is known to play an important
role in energy metabolism, has been reported to be constant
throughout the brain and resistant to change in several de-
generative brain diseases [4,15,16]. Cho is considered a marker for
cell turnover [4].
AMD is caused by the accumulation of waste products in the
tissues underneath the macula preventing normal retinal metab-
olism and leading to gradual retinal atrophy [17,18]. AMD affects
the retinal pigment epithelium and the photoreceptor layer, and
causes centrally located visual field defects. In glaucoma, visual
field loss starts peripherally. Progressive retinal ganglion cell loss
and optic nerve damage occur, in most cases, induced by an
elevated intra-ocular pressure [19,20]. In both cases, the retinal
damage is in continuous progress.
NAA is considered a major marker for neuronal integrity. If
progressive visual deprivation affects the metabolism of the adult
visual brain, lower local NAA concentrations in the occipital areas
are expected for the visual field defect groups when compared to
the control group. Our results, however, indicate no significant
differences in metabolite concentrations among the visual field
defect and the control groups. This can be interpreted as
degeneration not currently occurring or occurring at a very slow
rate preventing detectable changes.
MATERIALS AND METHODS
Subjects
Subjects with visual field defects were recruited from a database of
the Department of Ophthalmology of the University Medical
Center Groningen (Groningen, The Netherlands) and through
advertisements in magazines of patient associations. The group
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five males; mean age 72 years, range 52–82) and seven patients
with primary open-angle glaucoma (one female and six males;
mean age 73 years, range 61–84). Patients had to have, for
a minimum of 3 years, homonymous scotoma of at least 10
degrees diameter located centrally in at least one quadrant (as
recorded using the 30-2 program Sita Fast of Humphrey Field
Analyzer (Carl Zeiss Meditec, Dublin, California, USA)). Patients
with any other (neuro-) ophthalmic disease that might affect the
visual field were excluded.
For the control group, 12 healthy subjects (four female and eight
male; mean age 62 years, range 46–82) were recruited either by
advertisementina localnewspaper,orwerethe partnersofthe visual
field impaired participants. Control subjects were required to have
good visual acuity, not to have any visual field defect, and had to be
free of any ophthalmic, neurologic, or general health problem.
This study conformed to the tenets of the Declaration of
Helsinki and was approved by the medical review board of the
University Medical Center Groningen (Groningen, The Nether-
lands). All participants gave their informed written consent prior to
participation.
Materials and data acquisition
Single-voxel
1H-MRS was performed on a whole body 3.0 Tesla
Philips Intera scanner (Eindhoven, The Netherlands) in both the
left and right occipital pole using the standard T/R headcoil.
Scanning parameters were: TE=144ms, TR=2s and 128 signal
averages. To delineate the single-voxel or region of interest (ROI),
an elongated PRESS box was located in each hemispheres along
the calcarine sulcus as far to the back of the occipital pole and the
midline of the brain as possible while avoiding the inclusion of fat
and vasculature (figure 1). Total scan time was 5 min per
1H-MRS
voxel including acquisition of an unsuppressed water signal with
identical scanner settings.
Raw signals were post processed using the scanner software.
Post-processing included: 1) DC baseline correction using the last
10% of the signal. 2) Multiplication with a Gaussian and
exponential function resulting in 2 Hz line broadening and 1 Hz
line sharpening, respectively. 3) Zero filling from 1024 to 4096
samples. 4) Fourier transformation from the time to the frequency
domain. 5) Manual zero and first order phase correction.
Baseline and peak heights were determined manually by 3
independent operators, naı ¨ve with respect to the subject’s
classification. The measurements showed high correlation between
operators and were averaged.
Absolute metabolite concentrations were obtained by using the
unsuppressed water spectrum as a reference and assuming a water
volume percentage of 71%.
Statistics
Because no significant differences in metabolite concentrations
between the right and left hemispheres were detected, these values
were averaged. A one-way analysis of variance (ANOVA) was used
to determine any significant difference in the concentration of the
three metabolites (NAA, Cr and Cho) between the three groups
(AMD, glaucoma and controls).
RESULTS
Boxplots in figure 2 depict the averaged absolute concentrations of
each of the measured metabolites (NAA, Cr and Cho) for each
group (controls, AMD and glaucoma).
The one-way ANOVA between the three groups (AMD,
glaucoma and controls) showed no significant differences for any
of the three metabolites concentration. For the NAA concentra-
tions: F(2,23)=2.433, p,0.110; for the Cr concentrations:
F(2,23)=2.144, p,0.140; and for the Cho concentrations:
F(2,23)=1.754, p,0.195.
DISCUSSION
The main finding of this study is that, the NAA absolute levels in
the occipital brain of subjects with progressive visual field defects
(AMD and glaucoma) do not differ from the levels of a group of
control subjects. Hence, our results indicate that progressive
retinal visual field defects do not induce a measurable decrease in
NAA metabolite concentration in the visual brain areas.
AMD and glaucoma are both accompanied by progressive
visual field defects. As a consequence of that and because of the
retinotopic organisation of visual cortex, the section of cortex
corresponding to the dysfunctional area of the retina will no longer
receive input. Indeed, previous work by our group (submitted for
publication) showed that compared to controls, glaucoma, but not
AMD, patients showed a lower grey matter (GM) concentration as
Figure 1. Example of PRESS box position and spectra. Left: To delineate the single-voxel, an elongated PRESS box was located in each hemisphere
(here shown only in the left hemisphere) along the calcarine sulcus as far to the back of the occipital pole and the midline of the brain as possible
while avoiding the inclusion of fat and vasculature. Right: Example of spectra with Choline, Creatine and NAA peaks.
doi:10.1371/journal.pone.0000222.g001
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Knowing that non-stimulated cortical tissue tends to degenerate
[2] and that occurring cell loss is linked to a decrease in NAA
metabolite concentration [7,8,21], we would have expected to find
a reduction in NAA concentration in the visual brain of patients
suffering from progressive visual field defects, in particular those
with glaucoma. However, this is not the case. The fact that in our
sample there was no significant lower level of NAA suggests that
cell loss is not currently occurring in the occipital brain of our
patient groups. Longitudinal studies have emphasized that a sub-
stantial proportion of the decreases in NAA occurs in the acute
phase of cell degeneration [21].
Visual field degeneration in both AMD and glaucoma
progresses rather slowly [22]. This fact suggests that perhaps the
rate of progression is not high enough to evoke a decrease in NAA
metabolite concentration. Alternatively, the cortical area corre-
sponding to the affected retinal region may be too small to provoke
NAA changes that can be measured using single-voxel
1H-MRS.
On the other hand, ROI defined by our single-voxel may not
completely cover a degenerated region. In a previous magnetic
resonance imaging study (submitted for publication) we investi-
gated changes in GM. The area where differences were detected
did correspond to the projection zone of the damaged region of
the retina and was located in the anterior occipital lobe, along the
interhemispheric fissure. Because of its proximity to the fissure,
and consequently its vicinity to large amounts of pulsating blood,
this area is unsuitable for a single-voxel
1H-MRS ROI. As
a consequence, our present ROI locations may not have been
placed exactly in the cortical region previously associated with
a reduction in GM. This may have reduced our ability to
demonstrate small local changes in metabolite concentration.
Our results show no significant differences in Cr concentrations
between all three groups, as well. This was expected since this
metabolite has been observed to stay invariable throughout the
brain, also in the case of degenerative brain disorders [4,15,16].
Therefore, normalized changes in NAA are often assessed in
relation to Cr in terms of the ratio NAA/Cr [23]. However,
despite being resistant to change in degenerative diseases, we
preferred not to make use of the ratio NAA/Cr to measure cell
loss. Variations in Cr levels do occur as general loss together with
other metabolites in tissue necrosis [4]. Thus, if the process of
degeneration has already taken place and has stopped, NAA/Cr
levels will not decrease but both NAA and Cr compounds will be
comparably reduced as a result of the decay of cell number. The
ratio NAA/Cr will consequently be inadequate to evaluate any
changes in NAA.
Increases in Cho levels have been related to cell turnover [4].
Again, the fact that in our experiment no changes were
measured in Cho levels among all three groups reveals that no
cortical metabolic changes are associated with visual field
defects.
With the relatively small size of our experimental groups, the
present study has only the power to detect big effects. This is not
necessarily a disadvantage, because relatively large effects would
have had more potential clinical implication than subtle
differences. On the other hand, larger sample sizes could allow
identification of more subtle differences, the presence of which is
suggested by trends in our analysis.
Finally, AMD and glaucoma are both associated with the
occurrence of visual field defects but differ in the pathology. In
glaucoma, the optic nerve is damaged, while in AMD it remains
intact. We thus observe that nerve damage does not necessarily
affect NAA levels in the occipital region. Conversely, an
immunohistochemistry study targeting the mechanism behind
multiple sclerosis linked artificially induced optic nerve damage in
the rat to a decrease in NAA concentration, which returned to
normal level after 24 days [24]. Likewise, another group measured
a lower NAA concentration in the chiasm of two patients suffering
from optic neuritis. After visual field improvements, the NAA
levels increased [25]. This is in agreement with the idea that
reduced NAA concentrations can only be measured when
degenerative processes are currently taking place. In the case of
our patient groups, the absence of a detectable change suggests
either that occipital degeneration had already occurred (as
presumably is the case of glaucoma) or perhaps occurs at
a rate that is too slow to induce detectable changes in NAA
concentrations.
In conclusion, no significant differences in NAA, Cr and Cho
absolute concentrations were found in the occipital brain of
patients suffering from visual field defects when compared with
controls. The absence of a reduction in NAA concentrations
compared to controls most likely indicates that no degeneration is
currently occurring in the occipital region of AMD and glaucoma
patients. This absence might also be due to the fact that both
diseases progress at a very slow rate, which may prevent detectable
NAA changes. Further research concerning ocular disorders with
a faster degenerative process (for instance, as in ischemic optic
neuropathy or retinal vascular occlusion) could clarify this issue.
The application of
1H-MRS for the metabolic evaluation of
consequences of retinal visual field defects in the visual brain may
help understand disease symptoms and progression as well as the
mechanisms of brain plasticity in general.
Figure 2. Metabolite concentrations. Averaged absolute concentrations (in nM) of each of the measured metabolites (NAA, Cr and Cho) for each
group (controls, AMD and glaucoma). The ANOVA analysis between the three groups (AMD, glaucoma and controls) showed no significant
differences for any of the three metabolites concentration.
doi:10.1371/journal.pone.0000222.g002
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